Adjuvant Colorectal Cancer | QUASAR 2
Multi-centre International Study of capecitabine +/- bevacizumab as adjuvant treatment of colorectal cancer.
Schema
Summary
QUASAR 2 uses a new combination for adjuvant therapy: an oral chemotherapy drug (capecitabine) and a molecularly targeted therapy (bevacizumab), to define whether this is superior in efficacy and less in toxicity than capecitabine alone.
